Development of a Performance Model for Amputee Football Players

September 20, 2026 updated by: Ayşenur Gökşen, Tarsus University

Development and Evaluation of the Effectiveness of a Performance Model for Amputee Football Players

This study aims to investigate the effects of a cognitive game-based exercise program on cognitive and physical performance in amputee football players. Participants will complete a structured exercise program incorporating cognitive game activities designed to simultaneously stimulate cognitive and motor functions. Cognitive and physical performance outcomes will be assessed before and after the intervention. The findings are expected to provide evidence regarding the potential benefits of integrating cognitive game-based activities into exercise and rehabilitation programs for amputee football players.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Amputee football is a physically and cognitively demanding sport that requires rapid decision-making, attention, visuospatial processing, balance, coordination, and sport-specific motor performance. Therefore, training approaches that simultaneously target cognitive and physical functions may contribute to the performance of amputee football players.

This study aims to investigate the effects of a cognitive game-based exercise program on cognitive and physical performance in amputee football players. The intervention will incorporate structured cognitive game activities into an exercise program to provide simultaneous cognitive and motor stimulation. The activities will involve cognitive demands such as attention, concentration, planning, problem solving, decision-making, and visuospatial processing together with physical tasks.

Participants will undergo baseline assessments of cognitive and physical performance before the intervention. Following completion of the intervention program, the same outcome measures will be repeated to determine changes in cognitive and physical performance. The study will examine whether a structured cognitive game-based exercise approach can improve selected cognitive and physical performance outcomes in amputee football players.

The results may contribute to the development of multidimensional training approaches that integrate cognitive and motor components in amputee football and may provide a basis for future exercise and rehabilitation programs for athletes with lower-limb amputation.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
20

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Turkey (Türkiye)
      • Adana, Turkey (Türkiye)
        • Recruiting
        • Cukurova Unıversty
        • Contact:
          • Gonca İnce, Prof
          • Phone Number: 0(322) 338 70 0(322) 338 70 01
          • Email: gince@cu.edu.tr
        • Contact:
          • Veysel Alcan, PhD
          • Phone Number: 0(322) 338 70 01

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

Individuals with lower-limb amputation who actively participate in amputee football Regular participation in amputee football training Ability to understand and follow the study instructions Voluntary agreement to participate in the study

Exclusion Criteria:

Presence of an acute musculoskeletal injury that prevents participation in training or performance tests Presence of a medical condition that prevents safe participation in exercise or performance testing Inability to complete the cognitive or physical performance assessments Withdrawal from the study or failure to complete the intervention program

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Experimental Arm - Gince Cognitive Game-Based Exercise Group

Participants in this group will receive the Gince cognitive game-based exercise program in addition to their usual amputee football training. The program is designed to improve cognitive and physical performance through structured game-based activities.
Other: Gince Intelligence Game-Based Exercise Program

The intervention consists of a 10-session cognitive game-based exercise program using the Gince Intelligence Game. The program is administered in addition to routine amputee football training and is designed to stimulate cognitive and physical performance through game-based activities.
Experimental: Control Arm - Usual Training Group:

Participants in this group will continue their usual amputee football training without receiving the Gince cognitive game-based exercise program during the intervention period.
Other: Routine Training Group

Participants will continue their usual amputee football training program throughout the study period without receiving the additional Gince Intelligence Game-based exercise intervention.

Other Names:
  • Routine Amputee Football Training

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Stroop Test Performance
Time Frame: Baseline and immediately after completion of the intervention

Cognitive inhibitory control and selective attention will be assessed using the Stroop Test. Completion time will be recorded in seconds, and the number of errors will also be recorded. Changes from baseline to post-intervention will be evaluated
Baseline and immediately after completion of the intervention

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Secondary Outcome Measure - Illinois Agility Test Performance
Time Frame: Baseline and immediately after completion of the intervention

Agility performance will be assessed using the Illinois Agility Test. Completion time will be recorded in seconds. The best performance and mean performance will be recorded.

Time Frame: Baseline and immediately after completion of the intervention
Baseline and immediately after completion of the intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Tarsus University

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Cukurova University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
June 26, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 2, 2028

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 2, 2028

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 20, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 20, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 25, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 25, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 20, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 125C306
  • 125C306 (Other Grant/Funding Number: The Scientific and technological research council of Türkiye)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data are not planned to be shared due to participant confidentiality and data protection considerations.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings